DNA methylation in breast and colorectal cancers

Anshu Agrawal, Richard F Murphy and Devendra K Agrawal

Department of Biomedical Sciences, Creighton University School of Medicine, Omaha, NE, USA

DNA methylation is one of several epigenetic changes observed in cells. Aberrant methylation of tumor suppressor genes, proto-oncogenes, and vital cell cycle genes has led many scientists to investigate the underlying cellular mechanisms of DNA methylation under normal and pathological conditions. Although DNA methylation is necessary for normal mammalian embryogenesis, both hypo- and hypermethylation of DNA are frequently observed in carcinogenesis and other pathological disorders. DNA hypermethylation silences the transcription of many tumor suppressor genes, resulting in immortalization of tumor cells. The reverse process, demethylation and restoration of normal functional expression of genes, is augmented by DNA methylation inhibitors. Recent studies suggest that DNA hypomethylation may also control gene expression and chromosomal stability. However, the roles of and relationship between hypomethylation and hypermethylation are not well understood. This review provides a brief overview of the mechanism of DNA methylation, its relationship to extrinsic stimulation including dietary intake and aging, and of abnormally methylated DNA in breast and colorectal cancers, which could be used as prognostic and diagnostic markers.

During translation and transcription, DNA exerts its effects in cells through regulatory mechanisms including mRNA stabilization, transcription, and epigenetic changes.[1] The pattern of altered gene expression or epigenetic change is of major importance in common malignancies.[2,3] Methylation of the DNA, histone deacetylation, ubiquitination, and phosphorylation are examples of epigenetic change.[4] DNA methylation, unlike the other epigenetic changes, does not alter the nucleotide sequence.

Most cytosine-phosphoguanine (CpG) dinucleotides are unevenly distributed throughout the genome and remain in short stretches or clusters (500–2000 bp), called CpG islands.[5–7] These islands are located in the promoter region and are found in half of all human genes.[8] In mammals, DNA methylation occurs after replication, when a methyl group (CH_3) is added to the 5′ position of cytidyl residues in the dinucleotide sequence CpG[9,10] (Figure 1). Endonucleases, which normally degrade foreign DNA, regulate gene expression by silencing genes when the CpG is methylated.[11] CpG islands remain unmethylated in housekeeping genes and methylated or silenced in other genes.[12]

DNA is methylated by DNA methyltransferases (DNMTs), which transfer the methyl group from *S*-adenosylmethionine (SAM) to generate patterns of genomic methylation that silence genes[13–15] (Figure 1). The DNMTs known to date are DNMT1, DNMT2, DNMT3a, DNMT3b, and DNMT3L.[15,16] All methyltransferases have homology and different functions. DNMT1 maintains established methylation patterns in hemi-methylated genes by copying methylation patterns from the parent strand to the daughter and is expressed during the S-phase.[17] DNMT2, a small protein of 391 amino acids, is known to have weak DNA methyltransferase activity.[18] DNMT3a and DNTM3b, referred to as *de novo* methyltransferases, methylate unmethylated DNA. They initiate normal DNA methylation during embryonic development.[19] DNMT3L does not bind to SAM, but increases the binding of DNMT3a to SAM. Since DNMT3L-deficient mice are sterile, DNMT3L is likely to be essential in the methylation process.[19]

Overexpression of DNMTs can be lethal in animals as well as in human cancers.[20] DNMTs are involved in the downregulation of tumor suppressor

Figure 1 DNA methylation. SAM and other methyl donors bind to DNMTs to methylate the DNA that is tightly wrapped around the histones.


Figure 3 Known functional outcomes of DNA hypomethylation.

Figure 2 Two types of aberrant methylation, which elucidate certain actions.

Figure 4 Known functional outcomes of DNA hypermethylation.

genes and stimulation of proto-oncogenes.[21,22] Although DNMTs are important in DNA methylation, several findings indicate that DNMTs are not essential for the promotion of carcinogenesis.[23–25]

Hypo- and hypermethylation

When gene expression is altered due to DNA methylation, it is usually categorized as due to hypo-methylation or hypermethylation (Figure 2). DNA hypomethylation is associated with gene reactivation and chromosomal instabilities.[26,27] Functional outcomes of hypomethylation include the upregulation or overexpression of transcription of proto-oncogenes, increased recombination and mutation, X-chromosome inactivation, loss of imprinting, reactivation of transposable elements, and demethylation of xenobiotics[10,28,29] (Figure 3). Activation of proto-oncogenes, reactivation of transposable elements, and loss of imprinting of genes are the results of hypomethylation and all promote cancer.[30]

When CpG islands are hypermethylated, the activity of the regulatory proteins that promote transcription is restricted due to the tightly packed nucleosomes.[8] DNA hypermethylation is involved in gene repression and chromosomal instabilities.[31] Results of hypermethylation include suppression of tumor suppressor genes, chromatin condensation, and suppression of DNA repair genes (Figure 4). Tumor suppressor genes contain unmethylated CpG islands in their promoter regions and are methylated in various malignancies.[32–34] Both types of methylation occur simultaneously in various sporadic cancers and affect the function of human tumor suppressor genes and proto-oncogenes.[35]

Detection of DNA methylation

Currently, several methods are used to detect methylated DNA (Table 1).

Methylated DNA can be detected by converting unmethylated cytosine residues to uracil using sodium bisulfite modification, followed by polymerase chain reaction (PCR) to identify the unmethylated nucleotides.[36] Methylation-specific PCR (MSP) detects the methylation of CpG islands, but with higher specificity and sensitivity.[37] Quantitative real-time PCR (MethyLight or QM-MSP) is used to detect low levels of methylation that cannot be distinguished using MSP.[38,39]

Table 1 Methods of detection for methylated DNA sequences

Method	Acronym	Function	Reference
Methylation-specific PCR	MSP	Non-quantitative; quick way to determine if gene is methylated after sodium bisulfite modification	[36,37]
Quantitative multiplex methylation-specific PCR	QM-MSP or MethyLight	Quantitatively detects methylated alleles and can differentiate between monoallelic and biallelic sequences	[38,39]
McrBC-methylation-sensitive-arbitrarily-primed PCR	McrBC-msAP-PCR	Detects band intensity of methylated sites using enzyme McrBC	[40]
Methylated CpG island recovery assay	MIRA	Array based; uses genomic DNA to detect methylated sites	[41,42]
Combined bisulfite restriction analysis	COBRA	Combines PCR and restriction enzyme analysis to detect methylated sites	[43]
Differential methylation hybridization	DMH	Array based; can analyze > 50 000 genomic fragments for methylation at once	[44]
Microarray methylation assessment of a single mass	MMASS	Array based; compares genome-wide methylated to unmethylated sequences in a single sample	[45]
Methylation target array	MTA	Array based; detects hypermethylation of multiple loci in a variety of tumors	[46]

A modification of MSP, termed McrBC-methylation-sensitive-arbitrarily-primed-polymerase-chain-reaction (McrBC-msAP-PCR) requires methylation-specific GTP-dependent restriction endonuclease, McrBC, to detect differentially methylated sites within DNA, where hypermethylation and hypomethylation is observed by DNA fingerprint band intensity.[40] The procedure for the methylated CpG island recovery assay (MIRA) requires isolated and sonicated genomic DNA, instead of sodium bisulfite.[41] PCR reactions detect CpG island methylation after the DNA is incubated with a matrix containing methyl-CpG binding domain protein-2b (MBD2b) and methyl-CpG binding domain protein 3-like-1, which bind specifically to methylated DNA sequences.[41,42] MIRA can be used to study the methylation status of a wide array of genes in cancers, such as the lung.[42] Currently, other array-based methods are being developed to screen the methylation pattern of several genes.[39]

Differential methylation hybridization (DMH) is an oligonucleotide array-based method, which determines the extent of methylation of CpG islands by comparison with a reference sample.[44] Methylation-specific restriction enzymes (*Mse*I) are used to obtain intact CpG islands. The CpG islands are fluorescently labeled and after subsequent PCR, they are hybridized to arrayed oligonucleotides that can discriminate between methylated and unmethylated alleles in regions of interest. Microarray methylation assessment of single samples (MMASS) has been shown to be more sensitive and is an optimized method for detecting the methylated and unmethylated sequences within the entire genome.[45] MMASS uses the methylation-specific enzyme, McrBC, instead of *Mse*I. It is able to detect unmethylated sequences more effectively than DMH because McrBC only cleaves methylated sequences and does not require a reference sample.[45] Methylation target array (MTA) simultaneously determines whether or not genes and CpG islands

in multiple tumors are hypermethylated and can be correlated to clinicopathological features of the patient.[46] An advantage of MTA is that a single nylon filter can be used repeatedly to probe for various genes which are indicative of DNA methylation.[47]

DNA methylation and cancer: overview

Aberrant DNA methylation is one of the many potential causes for the abnormal growth of cancer cells, but it is also known to protect against intestinal cancer.[4] Different types of cancers are associated with methylation of tumor suppressor genes and proto-oncogenes, causing alterations in functional gene expression. Cancer-specific DNA methylation patterns have been detected in free-floating DNA released from dead cancer cells.[5,48] A decrease in the expression of tumor suppressor genes correlates with an increase in methylation of DNA in the promoter region.[49,50] Aberrant methylation of tumor suppressor genes in many cancers, resulting in the downregulation of transcriptional activation, has been reported.

In some cancers, both hypermethylation and hypomethylation are observed. Hypomethylation increases progressively with increasing malignancy grade in breast, ovarian, cervical, and brain cancers.[51] Breast and colorectal cancers are malignancies commonly caused by regional hypermutability or global hypomethylation.

DNA methylation and breast cancer

Many factors contribute to the pathogenesis of breast cancer, which is one of the most common malignancies among females. These factors include family history, nutrition, age, and epigenetic changes including DNA methylation. Methylation appears to be an early event in the etiology of breast

carcinogenesis, resulting in the activation of many oncogenes and silencing of tumor suppressors to promote proliferation of abnormal cells.[52,53] It is debatable, however, whether global hypomethylation or regional hypermethylation occurs first during the development of breast cancer, since the phenomena are independent processes. It is not known whether or not it is possible to inhibit carcinogenesis by inhibiting one of these processes and not the others. Numerous studies have revealed various genes, which are either hypo- or hypermethylated in breast cancer (Table 2).

Metastatic breast cancer requires the expression of multiple genes. Regional hypermethylation and global hypomethylation are involved in different stages of breast cancer.[76] Global hypomethylation could be a mechanism for late stages of breast cancer while local hypermethylation is plausible for early stages of breast cancer.[22,30] DNA methylation results in altered gene products including cell cycle regulators, steroid receptors, and cell adhesion molecules, which give rise to increased susceptibility to tumor development and decreased detoxification of carcinogens.[58] Alterations in the breast cancer susceptibility gene product (BRCA) accounts for half of the inherited breast carcinomas.[77] Its methylation is observed in breast and ovarian cancers, but not in colon and liver cancers, or

Table 2 Genes methylated in breast cancer

Gene	Description	Hypo/hyper	Reference
1-SYNU-CLEIN	Human breast cancer-specific gene 1	Hypo	[54]
c-myc	C-myelocytic leukemia	Hypo	[55]
MAGE	Melanoma-associated antigen	Hypo	[56]
NOEY2/ARHI	Ras homolog member 1	Hypo	[52]
Sat2	Satellite 2	Hypo	[57]
SATR1/SATR2	Satellite repeat 1/satellite repeat 2	Hypo	[57]
UPA	Urokinase plasminogen activator	Hypo	[54]
14-3-3sigma	14-3-3 sigma	Hyper	[58]
AK5	Adenylate kinase 5	Hyper	[59]
AMN	Amnionless homolog	Hyper	[59]
APC	Adenomatous polyposis coli	Hyper	[54]
BRCA1	Breast cancer	Hyper	[60]
CDH1	Cadherin 1	Hyper	[61]
CDKN2A	Cyclin-dependent kinase inhibitor 2A	Hyper	[17]
DAPK1	Death-associated protein kinase 1	Hyper	[54]
DCC	Deleted in colorectal carcinoma	Hyper	[59]
DSC3	Desmocollin 3	Hyper	[62]
ER	Estrogen receptor	Hyper	[8]
FOXA2	Forkhead box A2	Hyper	[59]
GJB2	Gap junction protein, beta 2 (Connexin 26)	Hyper	[59]
GSTP1	Glutathione S-transferase pi	Hyper	[32]
HIC-1	Hypermethylated in cancer 1	Hyper	[54]
HIN-1	Hairpin induced 1	Hyper	[63]
HME-1	Human epithelial cell marker 1	Hyper	[64]
HOXD11	Home box D11	Hyper	[59]
KLK6	Kallikrein 6	Hyper	[65]
KLK10/NES1	Kallikrein 10	Hyper	[66]
LATS1/LATS2	Large tumor suppressor 1 and 2	Hyper	[67]
LKB1/STK11	Serine/threonin protein kinase 11	Hyper	[68]
MGMT	Methylguanine methyltransferase	Hyper	[69]
NORE1	Novel Ras effector 1	Hyper	[70]
p14ARF	p14 alternate reading frame	Hyper	[71]
P16INK4a	p16 INK 4a	Hyper	[71]
p57KIP2	Cyclin-dependent kinase inhibitor 1C	Hyper	[72]
PCDH10	Protocadherin 10	Hyper	[59]
PR	Progesterone receptor	Hyper	[54]
Rad9	Rad9 homolog	Hyper	[73]
RASSF1A	Ras-association domain family protein 1A	Hyper	[54]
RUNX3	Human Runt-related transcription factor gene 3	Hyper	[74]
SIM1	Single-Minded homolog 1	Hyper	[59]
TDH	L-threonine dehydrogenase	Hyper	[59]
TIMP-3	Tissue inhibitor of metalloproteinases-3	Hyper	[54]
TMS1	Target of methylation-induced silencing 1	Hyper	[75]
Tropomyosin	Tropomyosin	Hyper	[59]
TSPAN-2	Tetraspan 2	Hyper	[59]
Twist	Twist	Hyper	[63]
WT-1	Wilms tumor 1	Hyper	[54]
XT3	X transporter protein 3	Hyper	[59]

leukemia indicating a tissue-specific process.[58] The frequency of methylation of this gene product is 38.5% in sporadic breast cancer.[60] Patients with a HER2/Neu-positive tumor indicate a highly aggressive breast cancer that requires special treatment, since it is amplified in 30% of invasive breast carcinomas.[55] DNA methylation is prevalent in the highly aggressive HER2/Neu-positive breast cancers; this gene is amplified in 30% of the cancers.[55] Increased aberrant methylation of steroid receptor genes and glycoproteins, such as progesterone receptor (PR) and E-cadherin, respectively, are associated with Her2/Neu-positive cancers. Hypermethylation of the GC-rich region and loss of expression in about 80% of invasive lobular carcinomas and lobular carcinoma *in situ* indicate the importance of the methylation of the CDH1 promoter in the pathogenesis of breast cancer.[78] Although many mechanisms, including mutation and loss of heterozygosity (LOH), are attributed to the downregulation of CDH1 in breast cancer, CDH1 promoter methylation is the mostly likely cause.[78,79]

The current criteria for detection and prognosis of breast cancer include an abnormal breast biopsy, tumor size, histological grade, estrogen and progesterone receptor status, and presence of the HER2/Neu oncogene.[80,81] Breast cancer can also be diagnosed by detecting the various aberrantly methylated genes. MSP is currently being used to detect the methylation status of various genes in breast biopsy tissues samples.[59] Presence of methylated DNA in the nipple duct lavage fluids, needle aspirates of the breast, and molecular staging of sentinel lymph nodes are also used to predict breast cancer development.[58] Ductal carcinoma *in situ* (DCIS), the most frequent breast cancer, can be detected early by observing the methylation of a panel of tumor suppressor or other cancer genes.[82,83] A 60-sample study with ductal lavage fluid from patients with a high risk of developing breast cancer and patients with breast cancer revealed that a nine-gene panel detection system using quantitative methylation-specific polymerase chain reaction (QM-MSP) can detect the rate of cancer cells more effectively than cytological and histological studies alone. Thus, earlier detection of breast cancer formation is possible.[84] Aberrant methylation of four genes was detected by QM-MSP in the plasma DNA of patients with breast cancer and tumors were successfully detected in eight of 24 patients with early-stage breast cancer.[85] Loss of MGMT (*O*(6)-methylguanine-DNA methyltransferase) was found to be associated with DNA methylation in a subset of breast cancers.[86] Although DNMT3b, a *de novo* methyl transferase, is overexpressed in 30% of breast cancers, its expression alone was not considered to be a prognostic factor for breast cancer progression.[87] Such studies highlight the importance of identifying specific methylated genes for diagnostic purposes, and for monitoring the efficacy of therapeutic modalities.

DNA methylation and colorectal cancer

Colorectal carcinoma is the third most common cancer in developed countries.[88] Although age and other demographic and environmental features, including gender, weight, nutritional intake, and alcohol consumption, are prognostic of colorectal cancer, epigenetic alterations are also causal.[89] Aberrant methylation is gradually acquired in the early stages of colorectal carcinoma.[90] As in breast cancer, both hypomethylation and hypermethylation of genes occur in colorectal cancer[91,92] (Table 3). The genes for p53 and for retinoic acid receptor (RAR) are hypermethylated in colorectal cancer.[108] A study with 65 colorectal carcinoma tissues demonstrated hypermethylation of the gene for the cell cycle regulatory protein, cyclin A1, in all cases, and for cadherin-13 in 65% cases.[96] Methylation did not correlate significantly with any clinicopathological feature, and changes in methylation appeared in an early phase of colon carcinogenesis.[96]

Aberrant methylation of some genes, including those for estrogen receptor α (ERα) and myoblast determination 1-protein (MYOD), correlate with aging and the prognosis of colorectal cancer.[109] UDP-glucoronosyltransferase (UGT1A1) gene expression is silenced and transcriptional activity is completely repressed in colon cancer cells due to direct methylation of its promoter region.[97] Treatment with either the inhibitors of histone deacetylase or demethylating agents restores normal expression of UGT1A1 in hypermethylated cells but has no effect on hypomethylated cells.[97]

Rhee *et al*[100] reported that DNA methyltransferases, DNMT1 and DNMT3b, are hypermethylated in colorectal cancer. Other studies suggest that methylation depends upon the type of cancer and that colorectal cancer can progress in the absence of DNMT1, as seen in the SW48 colorectal cancer cell line.[108,110] However, methylation can be reinitiated by introducing DNMT1 to the SW48 colon cancer cells lacking DNMT1 and DNMT3b.[111] Therefore, DNMT1 is potentially important in the hypermethylation of CpG islands in the promoter region of many genes in human cancer cells.

Colorectal tumors are often identified by the level of their microsatellite instability (MSI), which is a defect in the ability of repairing mistakes during DNA replication. MSI, stratified as MSI high, MSI low, and MSI stable, is commonly correlated with the degree of the colorectal cancer methylator phenotype (CIMP) when diagnosing colorectal cancer at the molecular level.[112] CIMP is distinguished as CIMP(+) or CIMP(−), although the existence of CIMP is still controversial. Supporters suggest an association with microsatellite instability (MSI) and proximal location of the colonic tumor.[113] A study with 106 primary colorectal tumors, however, did not support the existence of CIMP in human colorectal cancer and, consequently, it was regarded as a statistical artifact.[114] Colorectal cancer cannot be

Table 3 Genes methylated in colorectal cancer

Gene	Description	Hypo/hyper	Reference
CDH13	E-cadherin 13	Hypo	[6]
ER	Estrogen receptor	Hypo	[8]
hMLH1	MutL homolog 1	Hypo	[93]
MBD2	Methyl CpG binding protein	Hypo	[94]
MINT1	Methylated in tumor 1	Hypo	[95]
MINT3	Methylated in tumor 3	Hypo	[95]
SFRP1	Secreted frizzled-related protein 1	Hypo	[96]
UGT1A1	UDP-glucoronosyltransferase	Hypo	[97]
APC	Adenomatous polyposis coli	Hyper	[54]
CDKN2a	also known as p16	Hyper	[93]
CTDSPL	Carboxy-terminal domain small phosphatase like	Hyper	[98]
CIP1	Cyclin-dependent kinase inhibitor 1B	Hyper	[99]
COX2	Cyclooxygenase 2	Hyper	[96]
Cyclin A1	Cyclin A1	Hyper	[96]
DNMT1	DNA methyltransferase1	Hyper	[100]
DNMT3b	DNA methyltransferase 3b	Hyper	[100]
GATA-4/GATA-5	Transcription factor GATA-4	Hyper	[101]
HIC1	Hypermethylated in cancer 1	Hyper	[54]
HME-1	Human epithelial cell marker 1	Hyper	[102]
KCNK15	Potassium channel subfamily K member 15	Hyper	[98]
MAGEA1	Melanoma antigen, family A, 1	Hyper	[96]
MGMT	O(6)-methylguanine-DNA methyltransferase	Hyper	[93]
MS	Methionine synthase	Hyper	[103]
MTHFD1	Methylenetetrahydrofolate dehydrogenase	Hyper	[103]
MYOD-1	Myoblast determination 1-protein	Hyper	[103]
N33	Tumor suppressor candidate 3	Hyper	[96]
p14ARF	p14 alternate reading frame	Hyper	[71]
p16INK4a	p16 INK 4a	Hyper	[104]
p53	p53	Hyper	[38]
PTEN	Phosphatase and tensin homolog	Hyper	[96]
RAR	Retinoic acid receptor	Hyper	[96]
RASSF1A	Ras-association domain family protein 1A	Hyper	[69]
SFRP2-5	Secreted frizzled-related protein 2,3,4,5	Hyper	[105]
SLIT1/SLIT3	Slit homolog 1 and 3	Hyper	[106]
TFF1-3	Trefoil factor 1, 2, 3	Hyper	[101]
TIMP3	Tissue inhibitor of metalloproteinase 3	Hyper	[96]
TROPOMYOSIN	Tropomyosin	Hyper	[96]
TS	Thymidylate synthase	Hyper	[103]
UCHL1	Ubiquitin carboxy-terminal hydrolase 1	Hyper	[107]
UGT1A1	UDP-glucoronosyltransferase	Hyper	[97]
VHL	von Hippel–Lindau syndrome	Hyper	[8]
WNT9A	Wing-type member 9A	Hyper	[98]

identified on the basis of tumor methylation status and CIMP alone.

Hereditary non-polyposis colorectal cancer (HNPCC, Lynch syndrome) accounts for 2–4% of all colorectal cancers and aberrant methylation of the mismatch repair genes, human mutL homolog 1 (hMLH1) or hMLH2, are the basis for the cancer.[115] The combination of MSI-H and CIMP(−) is commonly observed in HNPCC.[112] In a study with 97 colorectal adenoma cases, hMLH1 methylation was more frequently observed in overweight or obese patients.[93] High-level MSI sporadic colon cancer and HNPCC share histological features, proximal tumor location, and presence of tumor-infiltrating lymphocytes. They differ, however, in having widespread promoter hypermethylation of specific genes such as hMLH1 and BRAF.[112] Fewer methylated genes are found in HNPCC than in high-level MSI colorectal tumors.[116]

Inhibitors of DNA methylation and demethylators

DNA methylation is a reversible process in which genes can be demethylated and restored to their original expression and function. DNA methylation inhibitors have been investigated as anticancer agents, since they block the activity of DNMTs and thus activate tumor suppressor genes[54] (Figure 5). The antisense oligonucleotide to human DNMT1, MG98, acts as a DNA methylation inhibitor and downregulates the activity of DNMT1. It has had promising results in clinical trials in treating cancers of the head and neck.[117] Recently, two novel inhibitors, NSC303530 and NSC401077, were shown to inhibit DNMTs *in vitro* and *in vivo* by blocking the active site of DNMT1.[118] These inhibitors have also been proposed as potential antitumor drugs.[118]

Figure 5 DNA methylation inhibitors. Successful inhibition of DNA methylation inhibitors (DNMTis) can prevent the suppression of tumor suppressor genes and continuous activation of proto-oncogenes.

Demethylation of aberrantly silenced genes can restore gene expression and function. Azacitidine (5-aza-C) and decitabine (5-aza-2′-deoxycytidine or 5-aza-2′-CdR) are two potent DNA demethylating agents. 5-aza-C was developed as a cancer chemotherapeutic agent and was thought to inhibit the enzymes that methylate the cytosine residues in DNA.[10,119] However, it is now considered that it demethylates methylated DNA and acts as an anti-tumor agent in many cancer cells.[120] Azacitidine is more toxic than its analog, decitabine.[22]

Decitabine has a short *in vivo* half-life and is able to reactivate previously silenced genes.[121,122] In clinical investigations in treating leukemia, decitabine was found to be most effective in an intensive dose with a short treatment time.[123] Decitabine is a potent cytotoxic agent and shows *in vitro* antitumor activity against breast cancer cells.[124] Both azacitidine and decitabine are effective in treating leukemia, which is characterized by hypermethylation.[35,125]

Zebularine, another potent demethylator, was found to be effective against cancer cells in many studies. In earlier studies, it was found to have toxic effects in cancer cell lines.[73] It has been shown to remove 25–60% of the methyl groups from methylated genes in a panel of seven human tumor cell lines.[94] The most promising features of the drug include its stability, low toxicity to normal cells, and that it can be taken orally.[126]

Administration of decitabine can reactivate silenced tumor suppressor genes and the histone deacetylase inhibitor, LAQ824 (LAQ), can activate genes related to cell cycle arrest.[123,127] These agents can synergistically produce greater antineoplastic effects on MDA-MB-231 breast cancer cells, thereby ensuring application of these agents for future clinical trials.[127] Lower doses of azacitidine and trichostatin A (TSA) are required to re-express ER in MDA-MB-231 (ER−) cells, when the drugs are used in combination than alone.[58] Thus, the combination

of drugs, which directly affects DNA methylation with drugs, causing other epigenetic changes, has considerable potential in increasing therapeutic affects.

Cancer Prevention, Dietary Intake, and DNA Methylation

Nutrition influences susceptibility to cancer. Approximately 35–50% of all cancers have a dietary component in their etiology.[128] Some food constituents can promote the onset of cancer. Deficiency of fiber, folic acid, methionine/choline, zinc, selenium, and chemicals found only in fruits and vegetables all can also cause cancer.[129] Excess intake of alcohol, animal fats, and salt promote cancer.[130] It was predicted that the incidence of cancer in vegetarian subjects would be lower than in those on a meat diet. Even though the vegetarian diet has a lower intake of vitamin B and lower content of methionine, both of which are essential for eventual methylation, this does not cause cancer.[131]

The role of folic acid in cancer is still controversial. The methyl groups of 5-methylenetetrahydrofolate is the precursor of the methyl group of methionine and thereby of SAM.[132] Low intake of folate combined with high alcohol intake can result in global hypomethylation and cause colorectal cancer. An increased risk of breast cancer occurs if folic acid is not metabolized correctly and the resultant supply of methyl groups to DNA in premenopausal women is insufficient.[113,132]

Low intake of folate is associated with an increased risk of colorectal cancer.[113] *In vitro* studies have indicated that colon cancer cell lines, when deprived of folic acid, have decreased viability.[132] Uracil is misincorporated into DNA as a result of folate deficiency. However, once a cancerous lesion is present, folate intake enhances tumor growth.[133] Methionine is taken as a nutritional supplement in adulthood to correct some genetically based epigenetic defects.[29] However, excess intake of methionine can also impair DNA methylation. Nevertheless, folate deficiency, leading to aberrant methylation of DNA, is not the sole cause of colon carcinogenesis.

Caffeic acid and chlorogenic acid, two catechol containing coffee polyphenols, inhibit DNA methylation.[134] They increase the formation of *S*-adenosyl-L-homocysteine (SAH), an inhibitor of DNA methylation. Partial inhibition of methylation in the promoter region of the retinoic acid receptor beta (RAR-β) gene by both caffeic acid and chlorgenic acid was demonstrated in breast cancer cell lines MCF-7 and MDA-MB-231.[135]

DNA Methylation and Aging

The risk of cancer increases with age. Only 10% of children have a chance of getting cancer, whereas

adults have a 35% chance, because methylation of CpG islands in non-malignant tissues increases but the total number of methylated cysteine residues decreases with age.[81,136,137] Individual genes are progressively methylated during aging due to chromosomal instability.[138] Genes that change methylation status with age are tissue specific. The c-myc gene is hypomethylated in the spleen and the c-fox is hypermethylated in the liver but not in the spleen.[28]

The normal colonic mucosa of older females has higher methylation levels, making these cells more susceptible to differentiate into malignant cells.[103,139] Hypermethylation does not always result in malignancy. For example, hypermethylation of the estrogen receptor gene was observed in both normal and cancer colon tissues, suggesting that the relationship between hypermethylation and age in cancer might not be simple, and requires a more careful analysis.[8]

Concluding remarks

DNA methylation is important in gene regulation and expression. It is imperative to learn more about the regulation of how this simple and basic process becomes aberrant. The complete biological mechanisms that initiate and maintain methylation of DNA need to be fully explained. Both hypomethylation and hypermethylation of proto-oncogenes and/or tumor suppressor genes occurs in various cancers. Many known genes are aberrantly methylated in breast and colorectal cancers.

In studies with established inhibitors of DNA methylation and demethylation, some genes were shown to be able to resume normal function. Zebularine was shown to be effective, without many toxic affects, in clinical trials. Despite constant efforts, the most effective and least toxic drugs are yet to be discovered. Indeed, even more questions arise from the plethora of recent advances in our understanding of the underlying mechanisms of methylation in cancer and other malignancies.

Acknowledgements

References

1 Nephew KP, Huang TH. Epigenetic gene silencing in cancer and progression. Cancer Lett 2003;190:125–133.

2 Baylin SB, Ohm JE. Epigenetic gene silencing in cancer—a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6:107–116.

3 Perez-Plasencia C, Duenas-Gonzalez A. Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy? Mol Cancer 2006;5:27.

4 Kim YI. Nutritional epigenetics: impact of folate deficiency on DNA methylation and colon cancer susceptibility. J Nutr 2005;135:2703–2709.

5 Laird PW, Jaenisch R. The role of DNA methylation in cancer genetic and epigenetic. Annu Rev Genet 1996; 30:441–464.

6 Feltus FA, Lee EK, Costello JF, *et al.* DNA motifs associated with aberrant CpG island methylation. Genomics 2006;5:572–579.

7 Vertino PM, Yen RW, Gao J, *et al. De novo* methylation of CpG island sequences in human fibroblast overexpressing DNA cytosine-5-methyltransferase. Mol Cell Biol 1996;16:4555–4565.

8 Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract 2005;2:S4–S11.

9 Bird A. DNA methylation patterns epigenetic memory. Genes Dev 2002;16:6–21.

10 Dunn BK. Hypomethylation: one side of a larger picture. Ann NY Acad Sci 2003;983:28–42.

11 Farrell WE. Epigenetic mechanisms of tumorigenesis. Horm Metab Res 2005;37:361–368.

12 Antequera F, Bird A. Number of CpG islands and genes in human and mouse. Proc Natl Acad Sci USA 1993; 90:11995–11999.

13 Ross SA. Diet and DNA methylation interactions in cancer prevention. Ann NY Acad Sci 2003;983: 197–207.

14 Brenner C, Fuks F. DNA methyltransferases: facts, clue, mysteries. Curr Top Microbiol Immunol 2006; 301:45–66.

15 Gopisetty G, Ramachandran K, Singal R. DNA methylation and apoptosis. Mol Immunol 2006;43: 1729–1740.

16 Singal R, Ginder GD. DNA methylation. Blood 1999;93:4059–4070.

17 Agoston AT, Argani P, Yegnasubramanian S, *et al.* Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. J Biol Chem 2005;280:18302–18310.

18 Chen T, Li E. Establishment and maintenance of DNA methylation patterns in mammals. Curr Top Microbiol Immunol 2006;301:179–201.

19 Jaenisch R. DNA methylation and imprinting: why bother? Trends Genet 1997;13:323–329.

20 Rodenhiser D, Mann M. Epigenetics and human disease: translating basic biology into clinical applications. CMAJ 2006;174:341–348.

21 Robertson KD, Ait-Si-Ali S, Yokochil T, *et al.* DNMT1 forms a complex with Rb, E2F1, and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 2000;25:338–342.

22 Szyf M. The DNA methylation machinery as a therapeutic target. Curr Drug Targets 2000;1:101–118.

23 Eads CA, Danenberg KD, Kawakami K, *et al.* CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res 1999;59:2302–2306.

24 Rhee I, Jair KW, Yen RW, *et al.* CpG methylation is maintained in human cancer cells lacking DNMT1. Nature 2000;404:1003–1007.

25 Li E, Beard C, Forster AC, et al. DNA methylation, genomic imprinting, and mammalian development. Cold Spring Harb Symp Quant Biol 1993;58: 297–305.

26 De Smet C, Loriot A, Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5′ region of gene MAGE-A1 in tumor cells. Mol Cell Biol 2004;24:4781–4790.

27 Eden A, Gaudet F, Waghmare A, et al. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003;300:455.

28 Richardson BC. Role of DNA methylation in the regulation of cell function: autoimmunity, aging and cancer. J Nutr 2002;132:2401S–2405S.

29 Waterland RA. Assessing the effects of high methionine intake on DNA methylation. J Nutr 2006;136: 1706S–1710S.

30 Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumors. J Pathol 2002;196:1–7.

31 Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3: 415–428.

32 Baylin SB, Herman JG, Graff JR. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141–196.

33 Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163–167.

34 Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225–3229.

35 Balch C, Montgomery JS, Paik HI. New anti-cancer strategies: epigenetic therapies and biomarkers. Front Biosci 2005;10:1897–1931.

36 Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93:9821–9826.

37 Sadri R, Hornsby PJ. Rapid analysis of DNA methylation using new restriction enzyme sites created by bisulfite modification. Nucleic Acids Res 1996;24: 5058–5059.

38 Ogino S, Brahmandam M, Kawasaki T, et al. Combined analysis of COX-2and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Neoplasia 2006;8: 458–464.

39 Wojdacz TK, Hansen LL. Techniques used in studies of age-related DNA methylation changes. Ann NY Acad Sci 2006;1067:479–487.

40 Tryndyak V, Kovalchuk O, Pogribyny IP. Identification of differentially methylated sites within unmethylated DNA domains in normal and cancer cells. Anal Biochem 2006;356:202–207.

41 Rauch T, Pfeifer GP. Methylated-CpG island recovery assay: a new technique for the rapid detection of methylated-CpG islands in cancer. Lab Invest 2005;85:1172–1180.

42 Rauch T, Li H, Wu X, et al. MIRA-assisted microarray analysis, a new technology for the determination of DNA methylation patterns, identifies frequent methylation of homeodomain-containing genes in lung cancer cells. Cancer Res 2006;66:7939–7947.

43 Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 1997;25:2532–2534.

44 Ho SM, Tang WY. Techniques used in studies of epigenetic dysregulation due to aberrant DNA methylation: an emphasis of fetal-based adult diseases. Reprod Toxicol 2007, Jan 19 [E-pub ahead of print].

45 Ibrahim AE, Thorne NP, Baird K, et al. MMASS: an optimized array-based method for assessing CpG island methylation. Nucleic Acids Res 2006;34:e136.

46 Chen C-M, Chen H-L, Hsiau TH-C, et al. Methylation target array for rapid analysis of CpG island hypermethylation in multiple tissue genomes. Am J Pathol 2003;163:37–45.

47 Ballestar E, Paz MF, Valle L, et al. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J 2003;22: 6335–6345.

48 Bastian PJ, Yegnasubramanian S, Palapattu GS, et al. Molecular biomarker in prostate cancer: the role of Cpg island hypermethylation. Euro Urol 2004;46: 698–708.

49 Schmutte C, Jones PA. Involvement of DNA methylation in human carcinogenesis. Biol Chem 1998;379: 377–388.

50 Salozhin SV, Prokhorchuk EB, Geogiev GP. Methylation of DNA—one of the major epigenetic markers. Biochem 2005;70:525–532.

51 Costello JF, Plass C. Methylation matters. J Med Genet 2001;38:285–303.

52 Jackson K, Yu MC, Arakwa K, et al. DNA hypomethylation is prevalent even in low-grade breast cancers. Cancer Biol Ther 2004;12:1225–1231.

53 Chekhun VF, Kulik GI, Yurchenko OV, et al. Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells. Cancer Lett 2006;231:87–93.

54 Szyf M, Pakneshan P, Rabbani SA. DNA methylation and breast cancer. Biochem Pharmacol 2004;68: 1187–1197.

55 Ross JS, Linette GP, Stec J, et al. Breast cancer biomarkers and molecular medicine. Expert Rev Mol Diagn 2003;3:573–585.

56 Wischnewski F, Pantel K, Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res 2006;4:339–349.

57 Narayan A, Ji W, Zhang X-Y, et al. Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int J Cancer 1998;77:833–838.

58 Yang X, Yan L, Davidson NE. DNA methylation in breast cancer. Endocr Relat Cancer 2001;8:115–127.

59 Miyamoto K, Fukutomi T, Akashi-Tanaka S, et al. Identification of 20 genes aberrantly methylated in human breast cancers. Int J Cancer 2005;116:407–414.

60 Birgisdottir V, Stefansson OA, Bodvarsdottir SK, et al. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res 2006; 8:R38.

61 Caldeira JRF, Prando EC, Quevedo FC, et al. CDH1 promotor hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer 2006;6:48.

62 Oshiro MM, Kim LJ, Wozhiak RJ, et al. Epigenetics silencing of DSC3 is a common event in human breast cancer. Breast Cancer Res 2005;7:R669–R680.

63 Fackler MJ, McVeigh M, Evron E, et al. DNA methylation of RASSF1A, HIN-1, RAR-beta, cyclin D2 and twist in in situ and invasive lobular breast carcinoma. Int J Cancer 2003;107:970–975.

64 Prasad GL, Valverius EM, McDuffie E, *et al.* Complementary DNA cloning of a novel epithelial cell marker protein, HME1, that may be downregulated in neoplastic mammary cells. Cell Growth Differ 1992;3: 507–513.

65 Pampalakis G, Sotiropoulou G. Multiple mechanisms underlie the aberrant expression of the human kallikrein 6 gene in breast cancer. Biol Chem 2006; 387:773–782.

66 Sidiropoulos M, Pampalakis G, Sotiropoulou G, *et al.* Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian, and prostate cancers. Tumor Biol 2005;26: 324–336.

67 Takahashi Y, Miyoshi Y, Takahata C, *et al.* Downregulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res 2005;11:1380–1385.

68 Fenton H, Carlile B, Montgomery EA, *et al.* LKB1 protein expression in human breast cancer. Appl Immunohistochem Mol Morphol 2006;14:146–153.

69 Esteller M. Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. Eur J Cancer 2000;36:2294–2300.

70 Hesson L, Dallol A, Minna JD, *et al.* NORE1A, a homologue of RASSF1A tumor suppressor gene is inactivated in human cancer. Oncogene 2003;22: 947–954.

71 Silva J, Silva JM, Dominguez G, *et al.* Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms. J Path 2003;199:289–297.

72 Kobatake T, Yano M, Toyooka S, *et al.* Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas. Oncol Rep 2004;12:1087–1092.

73 Cheng CK, Chow LWC, Loo WTY, *et al.* The cell cycle checkpoint gene Rad9 is a novel oncogene activated by 11q13 amplification and DNA methylation in breast cancer. Cancer Res 2005;65:8646–8654.

74 Lau QC, Raja E, Salto-Tellez M, *et al.* RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 2006;66:6512–6520.

75 Levine JJ, Stimson-Crider KM, Vertino PM. Effects of methylation on expression of TMS/ASC in human breast cancer cells. Oncogene 2003;22:3475–3488.

76 Van Zhee KJ, Calvano JE, Bisogna M. Hypomethylation and increased gene expression of p16INK4a in primary and metastatic breast carcinoma as compared to normal breast tissue. Oncogene 1998;16: 2723–2727.

77 Elstrodt F, Hollestelle A, Nagel JHA, *et al.* BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res 2006;66:41–45.

78 Droufakou S, Deshmane V, Roylance R, *et al.* Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer 2001;92:404–408.

79 Saario D, Moreno-Bueno G, Hardisson D, *et al.* Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer 2003;106: 208–215.

80 Lostumbo A, Mehta D, Setty S, *et al.* Flow cytometry: a new approach for the molecular profiling of breast cancer. Exp Mol Pathol 2006;80:46–53.

81 Laird PW. The power and the promise of DNA methylation markers. Nature Rev Cancer 2003;3: 253–266.

82 Evron E, Dooley WC, Umbricht CB, *et al.* Detection of breast cancer cells in ductal lavage fluid by methlyation-specific PCR. Lancet 2001;357:1335–1336.

83 Dua RS, Isacke CM, Gui GPH. The intraductal approach to breast cancer biomarker discovery. J Clin Oncol 2006;24:1209–1216.

84 Fackler MJ, Malone K, Zhang Z, *et al.* Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res 2006;12:3306–3310.

85 Hoque MO, Febg O, Toure P, *et al.* Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol 24;2006: 4262–4269.

86 Munot K, Bell SM, Lane S, *et al.* Pattern of expression of genes linked to epigenetic silencing in human breast cancer. Hum Pathol 2006;37:989–999.

87 Girault I, Tozlu S, Lidereau R, *et al.* Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res 2003;9:4415–4422.

88 Jubb AM, Quirke P, Oates AJ. DNA methylation, a biomarker for colorectal cancer: implications for screening and pathological utility. Ann NY Acad Sci 2003;983:251–267.

89 Grady WM. Epigenetic events in the colorectum and in colon cancer. Biochem Soc Trans 2005;33: 684–688.

90 Shames DS, Minna JD, Gazdar AF. DNA methylation in health, disease, and cancer. Curr Mol Med 2007;7: 85–102.

91 Bariol C, Suter C, Cheong K, *et al.* The relationship between hypomethylation and CpG island methylation in colorectal neoplasia. Am J Pathol 2003;162: 1361–1371.

92 Kennedy EP, Hamilton SR. Genetics of colorectal cancer. Semin Surg Oncol 1998;15:126–130.

93 Ye C, Shrubsole MJ, Cai Q, *et al.* Promoter hypermethylation status of the MGMT, hMLH1, and CDKN2A/p16 genes in non-neoplastic mucosa of patients with and without colorectal adenomas. Oncol Rep 2006;16:429–435.

94 Esteller M. CpG island methylation and histone modifications: biology and clinical significance. Ernst Schering Res Found Workshop 2006a;57: 115–126.

95 Wynter CV, Kambara T, Walsh MD, *et al.* DNA methylation patterns in adenomas from FAP, multiple adenoma and sporadic colorectal carcinoma patients. Int J Cancer 2006;118:907–915.

96 Xu XL, Yu J, Zhang HY, *et al.* Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J Gastroenterol 2004;10:341–354.

97 Gagnon JF, Bernard O, Villeneuve L, *et al.* Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer. Clin Cancer Res 2006; 12:1850–1858.

98 Shu J, Jelinek J, Chang H, *et al.* Silencing of bidirectional promoters by DNA methylation in tumorigenesis. Cancer Res 2006;66:5077–5084.

99 Ogino S, Kawasaki T, Kirkner GJ, *et al.* Down-regulation of p21 (CDKNIA/CIPI) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. J Path 2006;210:147–154.

100 Rhee I, Bachman KE, Park BH, *et al.* DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002;416:552–556.

101 Akiyama Y, Watkins N, Suzuki H, *et al.* GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biochem 2003;23:8429–8439.

102 Liu L, Zhang J, Bates S, *et al.* A methylation profile of *in vitro* immortalized human cell lines. Int J Oncol 2005;26:275–285.

103 Kawakami K, Ruszkiewicz A, Bennett G, *et al.* DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer. Br J Cancer 2006; 94:593–598.

104 Bachman KE, Park BH, Rajagopalan H, *et al.* Histone modifications and silencing prior to DNA Methylation of a tumor suppressor gene. Cancer Cell 2003;3:89–95.

105 Goebel B, Muller H, Reimer T, *et al.* Gene methylation data—a new challenge for bioinformaticians? Methods Inf Med 2005;44:516–519.

106 Dickinson RE, Dallol A, Bieche I, *et al.* Epigenetic inactivation of SLIT3 and SLIT1 genes in human cancers. Br J Cancer 2004;91:2071–2078.

107 Okochi-Takada E, Nakazawa K, Wakabayashi M, *et al.* Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int J Cancer 2006;119:1338–1344.

108 Vousden KH. p53: death star. Cell 2000;103:691–694.

109 Ahuja N, Li Q, Mohan AL, *et al.* Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res 1998;58:5489–5494.

110 Ting AH, Jair K, Schuebel KE, *et al.* Differential requirement for DNA methyltransferase 1 in maintaining human cancer cell gene promoter hypermethylation. Cancer Res 2006;66:729–735.

111 Jair KW, Bachman KE, Suzuki H, *et al. De novo* CpG island methylation in human cancer cells. Cancer Res 2006;66:682–692.

112 Jass JR, Walsh MD, Barker M, *et al.* Distinction between familial and sporadic forms of colorectal cancer showing DNA microsatellite instability. Eur J Cancer 2002;38:858–866.

113 Ulrich CM. Nutrigenetics in cancer research—folate metabolism and colorectal cancer. J Nutr 2005;135: 2698–2701.

114 Anacleto C, Leopoldino AM, Rossi B, *et al.* Colorectal cancer 'methylator phenotype': fact or artifact? Neoplasia 2005;7:331–335.

115 Gazzoli I, Loda M, Garber J, *et al.* A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the hMLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res 2002;62:3925–3928.

116 McGivern A, Wynter CVA, Whitehall VLJ, *et al.* Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam Cancer 2004;3:101–107.

117 Davis AJ, Gelmon KA, Siu LL. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest New Drugs 2003;21:85–97.

118 Siedlecki P, Boy RG, Musch T, *et al.* Discovery of two novel, small-molecule inhibitors of DNA methylation. J Med Chem 2006;49:678–683.

119 Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980;20:85–93.

120 Stresemann C, Brueckner B, Musch T, *et al.* Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 2006;66: 2794–2800.

121 Jones P. Effects of 5-azacytidine and its 2′-deoxyderivative on cell differentiation and DNA methylation. Pharmacol Ther 1985;28:17–27.

122 Fahrner JA, Eguchi S, Herman JG, *et al.* Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res 2002;62: 7213–7218.

123 Momparler RL, Bovenzi V. DNA methylation and cancer. J Cell Physiol 2000;183:145–154.

124 Bovenzi V, Le NL, Cote S, *et al.* DNA methylation of retinoic acid receptor beta in breast cancer and possible therapeutic role of 5-aza-2′-CdR. Anticancer Drugs 1999;10:471–476.

125 Esteller M. DNA methylation and cancer therapy: new developments and expectations. Curr Opin Oncol 2005;17:55–60.

126 Esteller M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer 2006b;94:176–183.

127 Hurtubise A, Momparler RL. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-aza-2′-deoxycytidine (decitabine) on human breast carcinoma cells. Cancer Chemother Pharmacol 2006;58:618–625.

128 Jacobs MM. Diet, nutrition and cancer research: an overview. Nutr Today 1993;27:19–23.

129 Dreosti IE. Nutrition, cancer, and aging. Ann NY Acad Sci 1998;854:371–377.

130 Gerber B, Muller H, Reimer T, *et al.* Nutrition and lifestyle factors on the risk of developing breast cancer. Breast Cancer Res Treat 2003;79:265–276.

131 Geisel J, Schorr H, Bodis M, *et al.* The vegetarian lifestyle and DNA methylation. Clin Chem Lab Med 2005;43:1164–1169.

132 Duthie SJ, Narayanan S, Brand GM, *et al.* Impact of folate deficiency on DNA stability. J Nutr 2002;132: 2444S–2449S.

133 Choi SW, Mason JB. Folate and carcinogenesis: an integrated scheme. J Nutr 2002;132:2350S–23505.

134 Lee WJ, Shim JY, Zhu BT. Mechanisms of inhibition of DNA methyltransferases by tea catechins and bio flavonoids. Mol Pharmacol 2005;68:1018–1030.

135 Lee WJ, Zhu BT. Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols. Carcinogenesis 2006;27:269–277.

136 Catania J, Fairweather DS. DNA methylation and cellular aging. Mutat Res 1991;256:283–293.

137 Richardson B, Yung R. Role of DNA methylation in the regulation of cell function. J Lab Clin Med 1999;134:333–340.

138 Issa JP. Aging, DNA methylation and cancer. Crit Rev Onco Hematol 1999;32:31–43.

139 Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000;16:168–174.